ATV2301 is an orally active anti-influenza agent (EC 50, H1N1 = 1.88 nM, H3N2 = 4.77 nM). ATV2301’s anti-influenza activity is due to its effects on polymerase acid protein (PA), nuclear protein (NP), and RNA-dependent RNA polymerase (RdRp) [1].
References:
[1]. Yongzhi Chen, et al. Discovery of Novel Thiophene-Based Baloxavir Derivatives as Potent Cap-Dependent Endonuclease Inhibitors for Influenza Treatment. J Med Chem. 2024 Dec 26;67(24):22039-22054.
References:
[1]. Yongzhi Chen, et al. Discovery of Novel Thiophene-Based Baloxavir Derivatives as Potent Cap-Dependent Endonuclease Inhibitors for Influenza Treatment. J Med Chem. 2024 Dec 26;67(24):22039-22054.